CD40 and triple-negative breast carcinoma: To determine the effect of anti-CD40 in another tumor model that is resistant to CTLA4i and radiation used as monotherapy and shows responses in a minority of mice treated with the combination of RT+CTLA4i (Fig. 10a–c, and Supplementary Fig. 22a), we used the AT3 mouse model of triple-negative breast cancer.